Roche Expands Precision Oncology Footprint with $595 Million Acquisition of Saga Diagnostics to Bolster Minimal Residual Disease Testing Capabilities
Roche has finalized a definitive agreement to acquire Saga Diagnostics, a specialist in ultra-sensitive molecular residual disease (MRD) testing, in...
June 30, 2025